Current Research Studies

A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy

OMS721-HCT-002 Narsopliamb

Condition(s): BMT
Phase: II

What is the goal of the study?

The purpose of this Phase 2 study is to evaluate the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of narsoplimab in paediatric-aged patients with thrombotic microangiopathies (TMA) following haematopoietic stem cell transplant (HSCT).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Sangeeta Hingorani
Study Team Member: Emily Pao, emily.pao@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.